Literature DB >> 19028927

Standards for the management of sickle cell disease in children.

M C Dick1.   

Abstract

Sickle cell disease is now the commonest genetic condition in England with a birth prevalence of 1 in 2000. It causes significant morbidity and mortality particularly in the early years unless prophylactic measures have been put in place. By the end of 2006 newborn screening had been introduced all over England, its prime aim being to minimise mortality from pneumococcal sepsis in the first few years of life. Plans are currently underway to roll out programmes in Scotland and Wales. Standards and guidelines for the care of children with sickle cell disease were written to accompany the newborn screening programme and to offer a management plan for those working in areas of low prevalence where resources and expertise were possibly less well developed. This article describes the existing evidence base for treatment and the current consensus of good practice. It is acknowledged that more work needs to be carried out to develop guidelines further.

Entities:  

Mesh:

Year:  2008        PMID: 19028927     DOI: 10.1136/adc.2007.116699

Source DB:  PubMed          Journal:  Arch Dis Child Educ Pract Ed        ISSN: 1743-0585            Impact factor:   1.309


  2 in total

1.  Community healthcare workers' perception of an educational intervention in the care of patients with sickle cell disease in Brazil.

Authors:  Ludmila Mourão Xavier Gomes; Thiago Luis de Andrade Barbosa; Elen Débora Souza Vieira; Lara Jhulian Tolentino Vieira; Karla Patrícia Ataíde Nery Castro; Igor Alcântara Pereira; Antônio Prates Caldeira; Heloísa de Carvalho Torres; Marcos Borato Viana
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-04-20       Impact factor: 2.576

2.  Quality of assistance provided to children with sickle cell disease by primary healthcare services.

Authors:  Ludmila Mourão Xavier Gomes; Tatiana Carvalho Reis; Magda Mendes Vieira; Thiago Luis de Andrade-Barbosa; Antônio Prates Caldeira
Journal:  Rev Bras Hematol Hemoter       Date:  2011
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.